Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15774MR)

This product GTTS-WQ15774MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15774MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5990MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ15115MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ2744MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ15666MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ7593MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ9598MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ13957MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ10460MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW